News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Nordic stocks fell, with Copenhagen's OMX20 plunging 2.12% to a five-year low and Oslo's OBX down 0.14%.
  • Poland's WIG30 dropped 1.0% as Media, Developers and Construction sectors led declines.
  • Citigroup shares fell about 4% after reports management held talks to buy a regional bank.
  • The dollar climbed to roughly ¥160, nearing Japan's suspected intervention threshold.
  • Anthropic launched Claude Mythos, triggering selling pressure in cybersecurity stocks over competitive concerns.
  • Analysts pitched Lumentum as a tactical long, citing photonics demand and recent S&P inclusion.

Latest Articles

H.C. Wainwright Lifts Biogen Price Target to $228, Citing Pipeline Diversification and Key Clinical Catalysts

H.C. Wainwright Lifts Biogen Price Target to $228, Citing Pipeline Diversification and Key Clinical Catalysts

H.C. Wainwright increased its price target on Biogen to $228 from $194 and reaffirmed a Buy rating, pointing to a broadened drug pipeline across renal, lupus and SMA indications. The firm highlighted the felzartamab AMR program, upcoming LEQEMBI IQLIK PDUFA and SPINRAZA High-Dose adoption as drivers that could shift Biogen's revenue mix despite ong…

Wedbush Starts Coverage on Zura Bio with Outperform, $15 Target

Wedbush Starts Coverage on Zura Bio with Outperform, $15 Target

Wedbush has begun coverage of Zura Bio Ltd. with an Outperform rating and a $15.00 price objective, noting clinical readouts and pipeline progress as key upside drivers. The stock trades well below the target but above InvestingPro's Fair Value estimate, and the company announced a CEO appointment effective January 21, 2026.

Hims & Hers Pulls Compounded GLP-1 Pill, BTIG Keeps Buy Rating

Hims & Hers Pulls Compounded GLP-1 Pill, BTIG Keeps Buy Rating

Hims & Hers Health has stopped offering its recently introduced compounded semaglutide pill following industry and regulatory discussions. The move follows signals from the FDA about enforcement against non-approved GLP-1 drugs. Despite the product withdrawal and a recent share-price decline, BTIG has maintained a Buy rating with a $60 price target…

Wolfe Research Holds Peerperform on PPG as Sales Momentum Offsets EPS Miss

Wolfe Research Holds Peerperform on PPG as Sales Momentum Offsets EPS Miss

Wolfe Research reiterated a Peerperform rating on PPG Industries, citing share-gain momentum driven by new, higher-tech products and expansion into broader end-market packages. The firm sees upside tied to improvements in core end markets such as aerospace and refinish but flagged that broader macroeconomic gains are needed to sustain recent progre…

Jefferies Cuts Molina Healthcare Price Target, Flags Medicaid MLR Risks

Jefferies Cuts Molina Healthcare Price Target, Flags Medicaid MLR Risks

Jefferies lowered its price objective for Molina Healthcare to $139 from $160 and kept a Hold rating, citing concerns around Medicaid medical loss ratio (MLR) in late 2026 tied to the Florida CMS contract. The firm expects 2027 EPS to fall year-over-year but slightly less than prior forecasts as the Florida contract matures. Recent corporate result…

Micron Shares Slip After Samsung Moves Up HBM4 Production Schedule

Micron Shares Slip After Samsung Moves Up HBM4 Production Schedule

Micron Technology shares declined 3.2% after reports that Samsung Electronics will begin large-scale production of next-generation HBM4 memory this month for use in Nvidia’s AI processors. Samsung has reportedly cleared Nvidia’s quality checks and secured purchase orders, timing its output to Nvidia’s Vera Rubin launch plans. The move heightens com…

Leerink Boosts Lantheus Price Target to $94 as Firm Flags 2026 Catalysts

Leerink Boosts Lantheus Price Target to $94 as Firm Flags 2026 Catalysts

Leerink Partners has raised its price target on Lantheus Holdings to $94.00 from $90.00 and kept an Outperform rating ahead of the company's fourth-quarter earnings report scheduled for February 19. The firm updated its model to reflect stronger Pylarify volume trends, progress toward an F-18 formulation and potential 2026 product catalysts, while …

Tokyo Rally Propels Asian Markets as Investors Eye U.S. Data

Tokyo Rally Propels Asian Markets as Investors Eye U.S. Data

Asian equities climbed after Japan's ruling party secured a decisive parliamentary majority, lifting the Nikkei to a record high. Global investors took a cautiously positive stance as Wall Street futures held steady following a chipmaker-led rebound. Attention now turns to a slate of U.S. economic releases this week, including a delayed January job…

Gold Extends Rally, Up Nearly 1% as Markets Await Key U.S. Data

Gold Extends Rally, Up Nearly 1% as Markets Await Key U.S. Data

Gold rose almost 1% on Monday, building on a roughly 4% jump on Friday, while silver advanced close to 5% after an almost 10% surge the prior trading day. The gains come as market participants wait for delayed U.S. jobs and inflation reports that could influence the Federal Reserve's policy outlook amid broader market uncertainty.